On the stock market since 1990, it operates in the world of health and science. It has 7,063 employees. Now — the numbers.
This is an established company with proven profits.
Revenue is spread across several lines; no single product carries the company.
An average decline of 8% a year over the last 4 years — the most striking risk in this picture.
The gap is $424.1M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 3 years, sales fell about 6% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The price action doesn’t yet back an upward turn. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 4/10.
On our five-subject report card, HOLX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: HOLX is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.